Business
Moderna’s stock has surged 488% in 2020: Is it a buy for 2021?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
All eyes were on the biotech Moderna (NASDAQ: MRNA) in 2020. It wasn’t quite a popular name in the pharmaceutical space, as it has no approved products on the market yet. But its sudden entry in the COVID-19 vaccine competition grabbed a lot of attention, and it became the second company to win approval in a race with dozens of players. No wonder its stock has surged 488% so far this year, while the S&P 500 has gained 16%.
On Dec. 11, Pfizer (NYSE: PFE) and its German biotech partner BioNTech (NASDAQ: BNTX) became the…
-
Business24 hours ago9 ASX shares including Nuix and PolyNovo dumped from ASX 200
-
Noosa News22 hours agoTrial for Clive Mensink, former director of Queensland Nickel, delayed due to ‘exceptional circumstances’
-
Business20 hours agoHow to build a $250,000 passive income portfolio starting from zero
-
Business23 hours ago4 reasons to buy Woolworths shares today